enVVeno Medical Corp (NVNO) company profile
Close on Nov 18, 2026Market cap $4.01MP/E –Yield –
About enVVeno Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
enVVeno Medical Corporation is a medical device company developing tissue-based bioprosthetic solutions to treat venous disease, specifically targeting patients with severe chronic venous insufficiency of the deep venous system. The company develops replacement venous valves to restore unidirectional blood flow toward the heart and lungs, counteracting blood pooling and high venous pressure in the lower legs. Its primary product pipeline centers on the enVVe System, a transcatheter, non-surgical replacement valve that includes a delivery device, accessories, nose cone, and crimping mechanism. The device aims to serve patients suffering from severe chronic venous insufficiency and related leg ulcers, with implant procedures intended for vascular surgeons, interventional radiologists, and interventional cardiologists.
The company conducts its development and manufacturing activities in a 14,507-square-foot leased facility located in Irvine, California. It has thirty-three full-time employees and holds intellectual property across global jurisdictions, including nine United States patents. enVVeno Medical Corporation maintains its corporate headquarters in Irvine, California.
Summary of the business section of enVVeno Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- enVVeno Medical Corp
- Founded
- 1999
- Headquarters
- Irvine, CA
- Address
- 70 Doppler 92618
- Phone
- (949) 261-2900
- Website
- envveno.com
- Employees
- 12, Dec 31, 2019
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- NVNO
- Former tickers
- HJLI until Oct 1, 2021
- Exchange
- Nasdaq
- IPO date
- Jun 1, 2018
- Shares outstanding
- 1M, Oct 27, 2026
- Public float
- $76.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-35 reverse, Jan 20, 2026; 1-for-25 reverse, Nov 30, 2020
- SEC CIK
- 1661053
- CUSIP
- 29415J205
- ISIN
- US29415J2050
- FIGI
- BBG000PVDC20
- Share class FIGI
- BBG001SRG4B9
- LEI
- 549300KF5KREFECSNV87
- EIN
- 33-0936180
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Andrew Berman | Chief Executive Officer, Director | 22,236 |
| Hamed Alavi | Chief Technology Officer | 8,334 |
| Marc H. Glickman | SVP & Chief Medical Officer | 1,600 |
| Jennifer Bright | Chief Financial Officer | – |
| Francis Duhay | Director | 2,351 |
| Matthew Jenusaitis | Director | 16,545 |
| Robert Gray | Director | 11,155 |
| Sanjay Shrivastava | Director | 9,288 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $583.76K | -$166.04K | $525.35K | $6 | – |
| FY2024 | $1.16M | $218.41K | $483.56K | $59 | – |
| FY2023 | $1.87M | $2.15M | $657.62K | $101 | – |
| FY2022 | $466.48K | -$1.02M | $453.93K | $77 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Robert A. Berman Chief Executive Officer | $500.00K | $232.50K | $400.51K | $28.12K | $1.16M | -38% |
| Craig Glynn Chief Financial Officer | $250.00K | $38.75K | – | $13.48K | $302.23K | -43% |
| Marc H. Glickman, M.D. Chief Medical Officer and Senior Vice President | $367.50K | $56.96K | $150.19K | $51.92K | $626.57K | -19% |
| Dr. Hamed Alavi Senior Vice President & Chief Technology Officer | $300.00K | $46.50K | $150.19K | $25.20K | $521.90K | -22% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 1, 2018
- Offer price
- $5.00
- Securities offered
- 1,500,000
- Gross proceeds
- $7.50M
- Exchange
- Nasdaq
- First trading day
- May 31, 2018
- First-day close
- $5.24+4.8%
- Lock-up ends (est.)
- Nov 27, 2018
“Per Unit Total Public offering price $ 5.00 $ 7,500,000 Underwriting discounts and commissions(1) $ 0.45 $ 675,000 Proceeds to us, before expenses $ 4.55 $ 6,825,000 (1) See “Underwriting” beginning on page 115 of this prospectus for a description of the compensation payable to the underwriters.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 10, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 21, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 26, 2023 | Delisting | Notice of delisting from exchange (Form 25) |
| Sep 22, 2021 | Name change | Name changed from Hancock Jaffe Laboratories, Inc. to enVVeno Medical Corp |
| Nov 17, 2020 | Late filing | Notification of late filing |
| Apr 20, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 25, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 18, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 30, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 1, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 12, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?